ALPMY
Astellas Pharma Inc Unsponsored ADR (ALPMY) [ST]
▼ 2.28%
prev close
ASTELLAS PHARMA UNSP/ADR
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
+1
1 buys · 0 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-02-27 | ALPMYAstellas Pharma Inc Unsponsored ADR | Buy | $15,001 - $50,000 | 1220d ago | — |
2023-02-27
Daniel Goldman
ALPMY
Amount
$15,001 - $50,000
Filed
1220d ago
Recent News
Powered by Polygon.io
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035
Oncolytic Virus Immunotherapy Market Landscape Report 2026: A $5 Opportunity by 2031 - Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insights
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
$5.14 Bn Castration-sensitive Prostate Cancer Market Insights, Epidemiology, and Forecasts, 2022-2026 & 2026-2036
Trade Timeline
Congressional activity, newest first
Daniel Goldman
2023-02-27 · Purchase
$15,001 - $50,000